CollPlant Biotechnologies Ltd (CLGN)

Nasdaq: CLGN · Orthopedic, Prosthetic & Surgical Appliances & Supplies · Rehovot, IL · filing with the SEC since 2015

Full chart Alerts Compare

Grade5.1

◀ Past 4.9● Present 4.4▶ Future 6.4

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of CollPlant Biotechnologies Ltd

Nine metrics read from its own filings, by tense

Headline grade

5.1/10

◀ Past4.930% of the headline

● Present4.440% of the headline

▶ Future6.430% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

4.9/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

7.8/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 33% of this tense · 78th percentile among 29 sector filers · read for itself

From the record

CollPlant Biotechnologies Ltd's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

2.2/10

What has it actually done, year after year?

-10.1% a year over 8 filed years; profitable in 1 of 8.

weight 45% of this tense · 22nd percentile among 25 sector filers · read for its customers

From the record

CollPlant Biotechnologies Ltd's 8 filed years say what it did: revenue went from $5 million in fiscal 2018 to $2 million in fiscal 2025, down 10.1% a year; it rose in 4 of 7 years; the deepest fall was 98% from fiscal 2021 to fiscal 2022; net income was positive in 1 of 8 of those years (its annual reports).

What it rests on

revenue growth over the filed span-10.1%bottom 10% of its family
the share of years revenue rosebottom 30% of its family
the share of filed years with a profitbottom 46% of its family
the deepest fall from a revenue peak98.1%bottom 2% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

6.0/10

How has it treated the people who own it?

SI estimate 6.0/10, confidence 35 of 100 (one part).

weight 22% of this tense · 60th percentile among 26 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the top 40% of 26 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 26 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: CollPlant Biotechnologies Ltd's shareholder treatment is put at 6.0 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 40% of 26 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.4/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

3.7/10

Is it financially healthy right now?

ROE -189%: lost 189¢ per shareholder dollar. Leverage 44%: owes 44¢ per asset dollar.

weight 45% of this tense · 37th percentile among 27 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, CollPlant Biotechnologies Ltd lost about 189 cents for every dollar of shareholders' money, and gross profitability: its products earned about 14 cents per dollar of everything the company owns. Leverage: it owed about 44 cents per dollar of assets, and net share issuance: its share count grew 6.5% over the year (the filed statements).

What it rests on

what it owes per dollar of assetstop 48% of its family
return on equitybottom 23% of its family
gross profit against assetsbottom 30% of its family
the share count against the year beforebottom 44% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

4.7/10

How strong is its position in its industry?

bottom 47% of 26 in its family; net margin -484.6%.

weight 33% of this tense · 47th percentile among 26 sector filers · read for its customers

From the record

CollPlant Biotechnologies Ltd's standing among 26 graded names in its industry family: revenue of $2 million in fiscal 2025 ranks in the bottom 21% by size; a net margin of -484.6% ranks in the bottom 21%; revenue growth of 99.4% a year over the last 3 filed years ranks in the top 2% (its annual reports).

What it rests on

revenue against the family$2.4Mbottom 21% of its family
net margin-484.6%bottom 21% of its family
three-year revenue growth99.4%top 2% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.3/10

What are the people in charge doing?

SI estimate 5.3/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 19 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 19 members with one.
What the record cannot read: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned: family median, 19 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: CollPlant Biotechnologies Ltd's leadership is put at 5.3 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 19 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

6.4/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed

6.1/10

How much room does it have to grow?

top 39% of 25 in its family for room to expand.

weight 45% of this tense · 61st percentile among 25 sector filers · read for itself

From the record

CollPlant Biotechnologies Ltd's room to grow, from the newest filed statements (fiscal 2025): cash of $6 million against no long-term debt tagged leaves 51.8% of its assets as net cash, top 17% of its family; cash from operations less capital spending is -398.4% of revenue (bottom 18%); a gross margin of 64.8% (top 42%); research spending of 345.3% of revenue (top 15%) (its annual report).

What it rests on

cash less debt against assets51.8%top 17% of its family
cash from operations less capital spending against revenue-398.4%bottom 18% of its family
gross margin64.8%top 42% of its family
research spending against revenue345.3%top 15% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

5.3/10

What could actually drive growth from here?

top 47% of 25 in its family for growth drivers.

weight 33% of this tense · 53rd percentile among 25 sector filers · read for its customers

From the record

CollPlant Biotechnologies Ltd's growth drivers, from the filed years to fiscal 2025: revenue grew 99.4% a year over the last three filed years against -10.1% over all 8, speeding up (top 2% of its family); the newest year grew 360.9% (top 2%); research spending grew -7.2% a year (bottom 15%); capital spending grew -72% a year (bottom 2%) (its annual reports). CollPlant Biotechnologies Ltd tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span+109.5 points a yeartop 2% of its family
the newest year's revenue growth360.9%top 2% of its family
three-year growth of research spending-7.2%bottom 15% of its family
three-year growth of capital spending-72.0%bottom 2% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

8.5/10

Did its newest year beat what its own record pointed to?

top 15% of 23 in its family for expectations against reality.

weight 22% of this tense · 85th percentile among 23 sector filers · read for its shareholders

From the record

CollPlant Biotechnologies Ltd's newest year against its own record: revenue of $2 million in fiscal 2025 came in 250.9% above the $676 thousand its prior three years' pace pointed to (top 2% of its family); net income of $11 million against a prior three-year average of $14 million (top 41%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 2%) (its annual reports).

What it rests on

revenue against the prior three years' pace250.9%top 2% of its family
net income against the prior three years' average+15%top 41% of its family
net margin against its prior averageup more than 100 pointstop 2% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton CLGN · research, not advice